Repro Med Systems, Inc. Provides Revenue Guidance for the Fiscal Year 2022
March 03, 2022 at 02:31 am IST
Share
Repro Med Systems, Inc. provided revenue guidance for the fiscal year 2022. For fiscal year 2022, the Company expects revenue growth in the low to mid double digits, or $26.0 to $27.0 million on a full year basis.
KORU Medical Systems, Inc. designs, manufactures, and markets proprietary portable and advanced medical devices primarily for the subcutaneous drug delivery market. The Company is focused on home and specialty infusion solutions. Its focus is primarily concentrated on its mechanical infusion products, the FREEDOM Infusion Systems, which include the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets, and Precision Flow Rate Tubing. The devices are used for infusions administered at home and in alternate care settings. Its infusion devices work together as a system to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains a balance between what a patientâs subcutaneous tissues can tolerate and what the system delivers.